Cargando…

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

Moxifloxacin is under development for expanded use against Mycobacterium tuberculosis. Rifampin is a mainstay of therapy. We examined the interaction of moxifloxacin plus rifampin for log-phase and nonreplicating persister (NRP) organisms. For this evaluation, we employed our hollow-fiber infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drusano, G. L., Sgambati, Nicole, Eichas, Adam, Brown, David L., Kulawy, Robert, Louie, Arnold
Formato:	Texto
Lenguaje:	English
Publicado:	American Society of Microbiology 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925073/ https://www.ncbi.nlm.nih.gov/pubmed/20802826 http://dx.doi.org/10.1128/mBio.00139-10

Ejemplares similares

Effect of Administration of Moxifloxacin plus Rifampin against Mycobacterium tuberculosis for 7 of 7 Days versus 5 of 7 Days in an In Vitro Pharmacodynamic System
por: Drusano, G. L., et al.
Publicado: (2011)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM)
por: Louie, Arnold, et al.
Publicado: (2017)

Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model
por: Jacobsson, Susanne, et al.
Publicado: (2021)

Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant Staphylococcus aureus: A Time–Kill Assay
por: Kang, Yu Ri, et al.
Publicado: (2023)

Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease
por: Converse, Paul J., et al.
Publicado: (2015)

Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model
por: Jacobsson, Susanne, et al.
Publicado: (2022)

Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections
por: Jacobsson, Susanne, et al.
Publicado: (2022)

Discordance in Mycobacterium tuberculosis Rifampin Susceptibility
por: Kalokhe, Ameeta S., et al.
Publicado: (2012)

Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae
por: Vedithi, Sundeep Chaitanya, et al.
Publicado: (2018)

Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis
por: Mirzaei, Rasoul, et al.
Publicado: (2022)

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
por: Sam, I-Ching, et al.
Publicado: (2006)

Efficacy of antibiotic treatment of implant-associated Staphylococcus aureus infections with moxifloxacin, flucloxacillin, rifampin, and combination therapy: an animal study
por: Greimel, Felix, et al.
Publicado: (2017)

Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy
por: Lenz, Shannon M., et al.
Publicado: (2020)

Mycobacterium tuberculosis Beijing Genotype Resistance to Transient Rifampin Exposure
por: den Hertog, Alice L., et al.
Publicado: (2014)

Publisher Correction: Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae
por: Vedithi, Sundeep Chaitanya, et al.
Publicado: (2018)

Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM)
por: Pires de Mello, Camilly P., et al.
Publicado: (2018)

Rifampin- or Capreomycin-Induced Remodeling of the Mycobacterium smegmatis Mycolic Acid Layer Is Mitigated in Synergistic Combinations with Cationic Antimicrobial Peptides
por: Man, DeDe Kwun-Wai, et al.
Publicado: (2018)

Novel approaches in the treatment of Hansen’s disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States
por: Franco-Paredes, Carlos, et al.
Publicado: (2022)

Distinct Effects of Moxifloxacin and Bedaquiline on Growing and ‘Non-Culturable’ Mycobacterium abscessus
por: Mulyukin, Andrey L., et al.
Publicado: (2023)

Two Antagonistic Microtubule Targeting Drugs Act Synergistically to Kill Cancer Cells
por: Peronne, Lauralie, et al.
Publicado: (2020)

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
por: Somoskovi, Akos, et al.
Publicado: (2001)

rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis
por: Li, Ma-chao, et al.
Publicado: (2021)

Genotyping of rifampin-resistant Mycobacterium tuberculosis isolates from western Turkey
por: Cavusoglu, Cengiz, et al.
Publicado: (2004)

1983. Oral Therapy with Rifampin Associated with Minocycline or Moxifloxacin in Vertebral Osteomyelitis due to Gram-Positive Micro-organisms: A Retrospective Study of 64 Cases
por: Gaspard, Laura, et al.
Publicado: (2018)

Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin
por: Wagner, Rudolph S, et al.
Publicado: (2010)

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice
por: Almeida, Deepak, et al.
Publicado: (2011)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

2565. In vitro synergistic bacterial killing of imipenem and ceftaroline against Mycobacterium abscessus; a static concentration time-kill analysis
por: Shin, Eunjeong, et al.
Publicado: (2023)

Performance Assessment of the BluePoint MycoID Plus Kit for Identification of Mycobacterium tuberculosis, Including Rifampin- and Isoniazid-resistant Isolates, and Nontuberculous Mycobacteria
por: Chien, Jung-Yien, et al.
Publicado: (2015)

Diverse Clinical Isolates of Mycobacterium tuberculosis Develop Macrophage-Induced Rifampin Tolerance
por: Adams, Kristin N, et al.
Publicado: (2019)

Etymologia: Rifampin
por: Henry, Ronnie
Publicado: (2018)

Treatment of Staphylococcal Device Infections: Synergistic Daptomycin With Ceftaroline Versus Rifampin-Adjunct Therapy
por: Chang, Amy T, et al.
Publicado: (2020)

Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model
por: Gupta, U.D., et al.
Publicado: (2015)

Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner
por: Iacobino, Angelo, et al.
Publicado: (2021)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin
por: Zaczek, Anna, et al.
Publicado: (2009)

Rifampin-Resistant Mycobacterium bovis BCG–Induced Disease in HIV-Infected Infant, Vietnam
por: Hong, Duc Nguyen, et al.
Publicado: (2013)

Direct detection of Mycobacterium tuberculosis rifampin resistance in bio-safe stained sputum smears
por: Lavania, Surabhi, et al.
Publicado: (2017)

How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?
por: Ng, Kamela C. S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9l8sup2hf01kqt6u62uf7mueo7